Hair Relaxer lawsuit update

Verified snapshot

The facts that anchor this dossier

A source-driven guide to MDL 3060 that separates the court's allegations from the Sister Study's observational findings, explains why Black women's exposure context matters, and avoids treating every straightener or cancer as interchangeable.

Federal proceeding

MDL 3060

Northern District of Illinois before Judge Mary M. Rowland.

Pending federal actions

11,877

JPML count as of July 1, 2026; 16,059 historical actions were reported.

Triggering research

2022 Sister Study

Frequent straightener use was associated with higher uterine-cancer incidence; the authors called for replication and chemical identification.

Other reported association

Ovarian cancer

A 2021 Sister Study analysis reported an association for frequent straightener/relaxer or pressing-product use, based on a limited number of cases.

Critical distinction

Association ≠ individual causation

Self-reported exposure, changing formulations, confounding, and product identification remain important.

Documented chronology

How the litigation reached this point

What MDL 3060 coordinates

The federal proceeding brings together lawsuits alleging that certain chemical hair relaxers or straighteners were defectively designed or inadequately warned about and caused cancers or other injuries. The JPML chose the Northern District of Illinois because common discovery would involve product development, marketing, testing, regulatory history, and the scientific evidence. Defendants opposed centralization and dispute liability. The transfer order did not decide that any product causes cancer.

The short-form complaint illustrates the individualized layer. Filed plaintiffs identify products, defendants, approximate use and diagnosis, injuries, and selected legal theories by incorporating a master complaint. A master pleading creates efficiency; it does not eliminate proof requirements. The court's plaintiff fact sheet asks for sworn product-use and medical information, underscoring that brand, formulation, dates, frequency, diagnosis, and records matter.

What the uterine-cancer study found

The 2022 Sister Study analysis followed 33,947 participants ages 35 to 74 who had a uterus at enrollment. Over an average 10.9 years, 378 uterine cancers were identified. Compared with never use in the previous year, ever use of straightening products was associated with a hazard ratio of 1.80, and frequent use—more than four times in the previous year—with a hazard ratio of 2.55. The study found no association for dyes, bleach, highlights, or perms in that analysis.

Those figures are relative estimates, not a prediction that any user will develop cancer. Product use was self-reported at baseline, brands and ingredients were not comprehensively identified, exposure could change after enrollment, and the number of cancers among frequent users was limited. The authors explicitly called the finding first epidemiologic evidence and asked for replication and identification of the chemicals that might drive the association.

The ovarian and breast findings add context, not certainty

A 2021 Sister Study analysis of 40,559 participants reported no ovarian-cancer association for ever use of the examined hair products, but frequent use of straighteners, relaxers, or pressing products was associated with higher incidence. The estimate was based on a much smaller outcome count than the overall cohort, making precision and replication important. A separate Sister Study analysis reported associations between straightener use and breast-cancer risk, again as observational evidence rather than product-specific proof.

Cancer is not a single outcome, and 'hair product' is not a single exposure. Uterine, ovarian, and breast cancers have different biology and risk factors. Relaxers that chemically alter curl pattern are not automatically the same as keratin smoothing treatments that release formaldehyde when heated. FDA's formaldehyde guidance concerns heat-activated smoothing products; it should not be used to claim that every relaxer in MDL 3060 contains or releases formaldehyde.

Why the racial context belongs in the story

The NIH reported that the uterine-cancer association did not statistically differ by race, but the public-health impact could be greater for Black women because use is more prevalent and often begins younger or occurs more frequently. That is exposure context, not a biological claim that race itself caused the outcome. The Sister Study cohort was racially diverse, but participants all had a sister with breast cancer, and findings still need confirmation in other populations.

A responsible account also recognizes the social setting without stereotyping users. Hair texture norms, workplace expectations, access to products and salons, marketing, and cultural practice can shape exposure. Those facts may explain why a product issue has unequal consequences while preserving the individual dignity of people who made ordinary grooming choices with the information available to them.

How to follow a docket this large

The July 2026 JPML report lists 11,877 pending actions and 16,059 historical actions, placing MDL 3060 among the largest active product-liability dockets. The difference between historical and pending totals reflects terminated or otherwise no-longer-pending actions; it does not reveal why each case left the pending column. Dismissal procedures, transfers, voluntary dismissals, and other case-specific events can all affect counts.

Watch official orders for expert-evidence, discovery, dispositive-motion, and trial-selection developments. Do not treat new filings as proof that science has strengthened, and do not use an old online deadline or dollar range as if it came from the court. Product containers, photographs, receipts, salon records, dates and frequency of use, pathology, and treatment records may help reconstruct an individual history. They cannot be reduced here to a determination of causation, qualification, limitations, or value.

Reader questions

Frequently asked questions